Skip to content
AlternativeMed

SPECIALTY TOPICS · GUIDE

Device-Specific Approval for Brain Stimulation

FDA clearance and approval for brain stimulation belong to one named device and one stated use. Here is how to read them, with real examples and what they do not mean.

Content last updated . This page has not been medically reviewed.

Back to Emerging Wellness Science
Quick answer

In the United States, the FDA reviews brain stimulation devices one device at a time. A clearance or approval covers a named device, made by a named company, for a stated use. It does not turn "brain stimulation" into an approved treatment, and it does not carry over to a device that only sounds similar. This page explains how to read those words. It is information only and is not medical or legal advice.

Three different FDA routes

The FDA uses different routes depending on risk and on whether a similar device already exists.

  • 510(k) clearance. The maker shows the device is substantially equivalent to a legally marketed device. The FDA letter "clears" it for sale.[1]
  • De Novo. A route for new kinds of devices with no earlier match, when the risk is low enough for Class I or II.[2]
  • Premarket approval (PMA). A review of safety and effectiveness for Class III devices, the highest-risk group.[3]

"Cleared" and "approved" are therefore not the same word. For brain stimulation they sit on top of a classification rule that is written for one kind of device and one use.

Worked examples read from the FDA's own records

The table lists what I read on the FDA pages this session (read 2026-10-22). It is a sample, not a complete list of devices.

DeviceRoute and dateStated use, in brief
NeuroStar TMS Therapy System, Model 1.1 (magnetic coil)510(k) K083538, decision 16 Dec 2008[4]Entry shows "Substantially Equivalent"; I did not read the 2008 indication wording
NeuroStar Advanced Therapy System, Version 3.7510(k) K230029, 4 Apr 2023[5]Depressive episodes and anxiety symptoms in adults with major depressive disorder (MDD) after an unsatisfactory antidepressant response; also an adjunct for adults with obsessive-compulsive disorder
BrainsWay Deep TMS System510(k) K222196, 31 May 2024[6]Depressive episodes and anxiety symptoms in adults with MDD after an unsatisfactory antidepressant response; prescription use
Flow FL-100 (home tDCS headset)PMA P230024, 8 Dec 2025[7]Moderate to severe MDD in the current episode, adults 18 and older, not considered treatment refractory to medication

Two lessons come from the table. First, every row states a condition and a population. Second, the same word, "TMS", appears on devices with different coils, makers and reviewed uses.

What a clearance or approval does not mean

  • Not every similar device. A TMS system cleared for depression does not make another company's system, or a different use, cleared. The regulation that defines repetitive TMS systems is itself written for treating symptoms of major depressive disorder.[8]
  • Not every claim in the ads. A cleared device is cleared for its stated use. Marketing claims beyond that use, such as memory or "focus," are marketing claims unless a regulator has reviewed them.
  • Not proof of large benefit. The FDA's own review of the Flow FL-100 described "a moderate level of uncertainty of benefit" because of unblinding, no prespecified clinically significant change on the main scale, and conflicting literature.[9] The device was still approved, which shows that approval and certainty are different things.
  • Not a clinic's word. A clinic offering a treatment does not establish approval. Ask for the maker, model and the FDA record number, then check the FDA database yourself.

Classification can change with the use

The FDA classifies cranial electrotherapy stimulators by intended use. They are Class II when intended to treat insomnia or anxiety, and Class III, needing premarket approval, when intended to treat depression. They are described as prescription devices.[10] The same electrical idea can therefore sit in different risk classes depending on what the maker says it treats.

Outside the United States

This page covers the United States. In the United Kingdom, NICE has published guidance on repetitive TMS for depression, reviewed seven studies and judged it safe enough and effective enough for use in the NHS.[11] Other countries use different rules, and I did not verify them here.

How to check a device claim

  1. Find the exact product name and model.
  2. Find the FDA record (510(k), De Novo or PMA number) for that exact model.
  3. Read the stated indication and whether it is prescription use.
  4. Compare it with what the seller says. Any gap is a marketing claim.

For the difference between clinic-grade and consumer devices, see clinical versus consumer brain stimulation devices. For how stimulation methods compare for depression, see neuromodulation for depression. For general ways to label evidence, see how we label evidence.

Frequently asked questions

Does "FDA cleared" mean a brain stimulation device works?

Cleared means the FDA found it substantially equivalent to a legally marketed device for a stated use. It is a different standard from approval of a new high-risk device.[1][3]

If one TMS device is cleared, are all TMS devices cleared?

No. Clearances are issued for specific devices. The FDA records I read name specific systems from specific makers, each with its own number.[5][6]

Is there an FDA-approved home brain stimulation device?

The FDA record I read shows one: the Flow FL-100, approved by PMA on 8 December 2025 for adults with moderate to severe major depressive disorder who are not considered treatment refractory to medication. This is one device and one use. I did not verify other home devices.[7]

Does approval cover memory or focus claims?

The records I read state depression-related uses only. Memory and focus claims are marketing claims unless a regulator has reviewed them.[5][7]

References
  1. U.S. Food and Drug Administration. Premarket Notification 510(k). Read 2026-10-22.
  2. U.S. Food and Drug Administration. De Novo Classification Request. Read 2026-10-22.
  3. U.S. Food and Drug Administration. Premarket Approval (PMA). Read 2026-10-22.
  4. U.S. Food and Drug Administration. 510(k) Premarket Notification database entry K083538, NeuroStar TMS Therapy System Model 1.1. Read 2026-10-22.
  5. U.S. Food and Drug Administration. 510(k) clearance letter and summary K230029, NeuroStar Advanced Therapy System (Version 3.7). Read 2026-10-22.
  6. U.S. Food and Drug Administration. 510(k) clearance letter and summary K222196, BrainsWay Deep TMS System. Read 2026-10-22.
  7. U.S. Food and Drug Administration. Premarket Approval database entry P230024, Flow FL-100. Read 2026-10-22.
  8. Electronic Code of Federal Regulations via Legal Information Institute. 21 CFR 882.5805, Repetitive transcranial magnetic stimulation system. Read 2026-10-22.
  9. U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data, PMA P230024 (Flow FL-100). Read 2026-10-22.
  10. Electronic Code of Federal Regulations via Legal Information Institute. 21 CFR 882.5800, Cranial electrotherapy stimulator. Read 2026-10-22.
  11. National Institute for Health and Care Excellence (UK). Repetitive transcranial magnetic stimulation for depression, HTG396: benefits and risks (public information). Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.